Lake Street raised the firm’s price target on Inspire Medical to $270 from $240 and keeps a Buy rating on the shares after the company released Q4 results and 2024 revenue guidance was reiterated. Inspire “had another strong growth performance in Q4, resolved the prior authorization challenges from Q3, and guided to 2H24 profitability,” the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on INSP:
- Lost Money in MBLY, BNTX, DADA, INSP or ON? Class Action Suits Filed, Seeking Recovery
- Inspire Medical Systems Engages Investors with Upcoming Meetings
- Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results and Reaffirms 2024 Outlook
- Inspire Medical resumed with an Overweight at KeyBanc
- Inspire Medical Announces Leadership Changes and New Chair
